In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.62.
According to TipRanks, Mamtani is an analyst with an average return of -12.1% and a 31.80% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as TG Therapeutics, Agenus, and Arrowhead Pharmaceuticals.
Currently, the analyst consensus on MiNK Therapeutics is a Strong Buy with an average price target of $7.00, representing a 332.10% upside. In a report released today, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
INKT market cap is currently $54.94M and has a P/E ratio of -2.11.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other life-threatening illnesses.
Read More on INKT:
- MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
- MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
- MiNK Therapeutics announces clinical data of allogeneic iNKT cells
- MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
- MiNK Therapeutics price target lowered to $3 from $4 at Evercore ISI
